Accordingly, blocking PD-1/PD-L1 signaling has shown great efficacy in various cancers, however in a large proportion of patients PD-1/PD-L1 blockade shows limited success, highlighting the importance of understanding underlying mechanisms of checkpoint inhibitor blockade as well as defining biomarkers to predict treatment success (39). Here, CD274 is linked to cancer.